Made Scientific Adds 85,000 Sq. Ft. Cell Therapy GMP Site

Made Scientific has acquired an 85,000-square-foot clinical- to commercial-scale cell therapy manufacturing facility in East Norriton, Pa., from National Resilience, expanding the company's US East Coast good manufacturing practice (GMP) network to approximately 145,000 square feet and 15 qualified GMP manufacturing suites, the company announced September 21, 2026.¹ The transaction closed September 18, 2026, and the facility was operational at close, allowing sponsors to begin onboarding programs immediately, according to Made Scientific.¹

"The acquisition of an operational facility with an experienced manufacturing team represents a significant advance in our ability to support clients from clinical to commercial," said Syed T. Husain, chairman and CEO of Made Scientific, in a company press release.¹ "East Norriton provides that capacity today, supported by a demonstrated GMP operating history, and enables us to onboard client programs immediately rather than at the conclusion of a multi-year build."

What capabilities does the East Norriton facility add?

The East Norriton site and its manufacturing team have executed 145 GMP batches to date across multiple autologous and allogeneic cell therapy programs, including chimeric antigen receptor T cell (CAR-T) and B-cell therapies. The facility includes 8 Grade B/C cleanrooms, a Grade C ballroom, and a Grade B fill/finish suite, plus 30,000 square feet of expansion space designed to support up to 8 additional ballrooms. Made Scientific plans to equip the site with scalable 3D bioreactor platforms of up to 200 L, automated fill/finish, and lyophilization capacity, the company stated in the release.¹

What did Resilience say about the divestiture?

"Over the past year and a half, we have taken deliberate steps to reaffirm the purpose of our company, which is to broaden patient access to complex medicines and protect biopharmaceutical supply chains against disruption," said William S. Marth, president and CEO of Resilience, in a separate company release.² Resilience described the East Norriton sale as part of a more focused operating model intended to streamline its operations and strengthen long-term value creation.²

How does this move fit into the broader cell therapy manufacturing landscape?

Resilience's divestiture comes amid a broader pattern of retreat from ex vivo cell therapy manufacturing across the industry. In the weeks before the East Norriton sale, ArsenalBio halted development of its ex vivo CAR T-cell programs entirely, cutting about 99 of its 127 employees to redirect toward in vivo-engineered CAR-T therapies, and TScan Therapeutics paused its phase 3 ALLOHA-2 trial and cut approximately 75% of its workforce to prioritize in vivo TCR-T therapy, both citing the cost, complexity, and patient-access limitations inherent to ex vivo manufacturing.³ Separately, Bristol Myers Squibb terminated a manufacturing partnership worth up to $380 million with automation specialist Cellares after determining its platform could not meet requirements for commercial production of lisocabtagene maraleucel (Breyanzi), triggering approximately 100 layoffs.³ Made Scientific said the addition of the East Norriton site comes as the broader cell therapy contract development and manufacturing organization sector consolidates, with capacity leaving the market even as more therapies advance into late-phase trials and regulatory review.¹

What's next for Made Scientific?

The company said its expanded network supports client programs spanning mesenchymal stem cell, secretome, exosome, and senolytic therapies, alongside immune-cell, induced pluripotent stem cell-derived, and engineered-tissue programs supported at its Princeton, NJ, facility, and clients may transfer existing processes into the site or adopt Made Scientific's ReadyMADE platforms across multiple modalities.¹ The company is preparing its Princeton facility for a commercial-stage FDA pre-licensure inspection in early 2027, with the East Norriton facility to follow.¹

What are the limitations?

Financial terms of the acquisition were not disclosed. While the East Norriton facility has an established GMP operating history under its prior owner, its performance and inspection outcomes under Made Scientific's ownership and quality systems have not yet been established.

References

1. Made Scientific. Made Scientific expands US GMP cell therapy network with 85,000 sq. ft. Pennsylvania acquisition—operational on day one. Press release. Published September 21, 2026. Accessed September 22, 2026. https://madescientific.com/news/made-scientific-expands-u.s.-gmp-cell-therapy-network-with-85000-sq.-ft.-pennsylvania-acquisition-operational-on-day-one
2. National Resilience. Resilience further advances North American manufacturing strategy transformation. Press release. Published September 21, 2026. Accessed September 22, 2026. https://resilience.com/news/resilience-further-advances-north-american-manufacturing-strategy-transformation
3. Schoenthaler E. As companies flee ex vivo cell therapy, even automated manufacturing platforms face validation hurdles. BioPharm International. Published September 14, 2026. Accessed September 22, 2026. https://www.biopharminternational.com/view/as-companies-flee-ex-vivo-cell-therapy-even-automated-manufacturing-platforms-face-validation-hurdles